AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES

## 1Q24 Results Conference Call & Webcast

May 9, 2024



## **Forward-Looking Statements**

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forwardlooking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities and pricing and reimbursement authorities, are based on current information. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that required regulatory inspections may be delayed or not be successful and delay or prevent product approval; the potential that we may not be successful in negotiations with pricing and reimbursement authorities; the potential that we may not be successful in commercializing Galafold<sup>®</sup> and/or Pombiliti<sup>®</sup> and Opfolda<sup>®</sup> in Europe, the UK, the US and other geographies; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we may not be able to manufacture or supply sufficient clinical or commercial products; and the potential that we will need additional funding to complete all of our studies, the manufacturing, and commercialization of our products. With respect to statements regarding corporate financial guidance and financial goals and the expected attainment of such goals and projections of the Company's revenue, non-GAAP profitability and cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2023, and on Form 10-Q for the guarter ended March 31, 2024, to be filed today. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

#### Non-GAAP Financial Measures

In addition to financial information prepared in accordance with U.S. GAAP, this presentation also contains adjusted financial measures that we believe provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information. These adjusted financial measures are non-GAAP measures and should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. We typically exclude certain GAAP items that management does not believe affect our basic operations and that do not meet the GAAP definition of unusual or non-recurring items. Other companies may define these measures in different ways. When we provide our expectation for non-GAAP operating expenses on a forward-looking basis, a reconciliation of the differences between the non-GAAP expectation and the corresponding GAAP measure generally is not available without unreasonable effort due to potentially high variability, complexity and low visibility as to the items that would be excluded from the GAAP measure in the relevant future period, such as unusual gains or losses. The variability of the excluded items may have a significant, and potentially unpredictable, impact on our future GAAP results.



## **A Rare Company**

### A leading biotech company projected to deliver 2024 total revenue growth of 25%-30%<sup>1</sup>





## 2024 Strategic Priorities

A Transformative Year Ahead for Amicus





# Galafold® (migalastat) Continued Growth

Building a leadership position in the treatment of Fabry disease





### 2024 Galafold Success (as of March 31, 2024)


Galafold is the only approved oral treatment option in Fabry disease





## **Galafold Performance**

### Q1 2024 Galafold reported revenue growth of +16% at CER to \$99.4M



\$438M-\$454M<sup>1</sup>

 Global mix of switch (~42%) and previously untreated patients (~58%)<sup>2</sup>

 Expect non-linear quarterly growth to continue due to uneven ordering patterns and FX fluctuations

> **Distribution of Galafold revenue** by quarter over previous 5 years:

	Q1	Q2	Q3	Q4
5 Year Avg.	22%	24%	26%	28%

**Raising FY 2024 Galafold growth guidance to 13%-17% at CER** 



## **Key Growth Drivers for 2024**

Highest patient demand in last four years lays strong foundation for continued double-digit Galafold growth in 2024

- Expanding market through uptake in naïve population as well as geographic and label expansion
- Increasing patient identification through ongoing medical education, screening, and improved diagnostics
- Driving market share of treated amenable patients through excellent execution
- Maintaining >90% adherence and compliance through HCP and patient education and support





## Pombiliti<sup>®</sup> (cipaglucosidase alfa-atga) + Opfolda<sup>®</sup> (miglustat)

Potential to establish a new standard of care for people living with late-onset Pompe disease





## **Pombiliti + Opfolda Performance**

Q1 2024 revenue of \$11M, up +30% from Q4 2023, provides strong foundation for 2024



### Guiding to \$62M to \$67M in FY 2024 Pombiliti + Opfolda Revenue<sup>1</sup>



## Successful Global Launch of Pombiliti + Opfolda Underway

### Focus in 2024 is on maximizing the number of patients on therapy by year end





## **Regulatory and Clinical Updates**


### Continuing to build the body of evidence and expand commercial access

- >10 reimbursement dossiers and multiple regulatory submissions throughout 2024
- Ongoing clinical studies in children with late-onset Pompe disease (LOPD) and infantile-onset Pompe disease (IOPD)
- Amicus registry for Pompe disease to continue generating evidence on differentiated MOA and long-term effect
- Significant presence at WORLDSymposium<sup>™</sup> 2024 with 11 posters and an oral presentation highlighting work in Fabry and Pompe



# **Corporate Outlook**

Delivering on our mission for patients and shareholders





## **Q1 2024 Select Financial Results**

### Q1 2024 revenue of \$110M, up 28% and net loss reduced

(in thousands, except per share data)	Mar. 31, 2024	
(in mousullus, except per shure untu)	Wiar. 51, 2024	Mar. 31, 2023
Product Revenue	\$110,403	\$86,270
Cost of Goods Sold	13,567	6,942
R&D Expense	28,329	41,499
SG&A Expense	88,029	73,957
Changes in Fair Value of Contingent Consideration	-	251
Restructuring Charges	6,045	-
Depreciation and Amortization	2,154	1,257
Loss from Operations	(27,721)	(37,636)
Interest Income	1,540	2,199
Interest Expense	(12,436)	(11,844)
Other Expense	(4,966)	(5,938)
Income Tax (Expense) Benefit	(4,836)	287
Net Loss	(48,419)	(52,932)
Net Loss Per Share	(0.16)	(0.18)



14

## **Updated Full-Year 2024 Guidance**

	Updated Guidance	
		Previous Guidance
Total Revenue Growth <sup>1</sup>	25% to 30%	-
Galafold Revenue Growth <sup>1</sup>	13% to 17%	11% to 16%
Pombiliti + Opfolda Revenue <sup>1</sup>	\$62M to \$67M	-
Non-GAAP Operating Expense	\$345M to \$365M	\$345M to \$365M

**Guiding to full-year 2024 non-GAAP profitability** 



## **Positioned for Significant Value Creation in 2024**

Unlocking the value of two unique commercial therapies in sizeable and growing markets








Accelerating total revenue growth Delivering full-year non-GAAP<sup>1</sup> profitability Clear line of sight to generating positive cashflow



<sup>1</sup> Non-GAAP Net (Loss) Income defined as GAAP Net (Loss) Income excluding the impact of stock-based compensation expense, changes in fair value of contingent consideration, loss on impairment of assets, depreciation and amortization, acquisition related income (expense), loss on extinguishment of debt, restructuring charges and income taxes.

### Ultimate Measure of Success: Impacting the Lives of People Living with Rare Diseases

17





# Appendix



## Appendix I

### Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands)

### (Unaudited)

	Three Months Ended March 31,				
	2024	2023			
Total operating expenses - as reported GAAP	\$ 124,557	\$ 116,964			
Research and development:					
Stock-based compensation	4,871	8,490			
Selling, general and administrative:					
Stock-based compensation	25,932	26,404			
Restructuring charges	6,045	_			
Changes in fair value of contingent	_	251			
consideration payable					
Depreciation and amortization	2,154	1,257			
Total operating expense adjustments to reported	39,002	36,402			
GAAP					
Total operating expenses - as adjusted	\$ 85,555	\$ 80,562			



## Appendix "

Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands, except share and per share amounts) *(Unaudited)* 

	Three Months Ended March 31,			
	2024	2023		
GAAP net loss	\$ (48,419)	\$ (52,932)		
Share-based compensation	30,803	34,894		
Changes in fair value of contingent consideration payable	_	251		
Depreciation and amortization	2,154	1,257		
Restructuring charges	6,045	—		
Income tax expense (benefit)	4,836	(287)		
Non-GAAP net loss	\$ (4,581)	\$ (16,817)		
Non-GAAP net loss attributable to common stockholders per common share — basic and diluted	\$ (0.02)	\$ (0.06)		
Weighted-average common shares outstanding — basic and diluted	302,903,009	291,336,750		



## **Environmental, Social, & Governance (ESG) Snapshot**

### **Who We Serve**

Programs we invest in have 3 key characteristics: Address a rare genetic disease

First-in-class or best-in-class

Impart meaningful benefit for patients

### **Environmental** Management

Committed to producing transformative medicines for people living with rare diseases while practicing environmental responsibility and adhering to sustainability best practices in our operations.

**0%** Amicus-owned Direct Manufacturing and Related Scope 1 and Scope 2 Emissions

(as of December 31, 2023) **Global Employees** 

517

% Female Employees 58%

#### (as of March 31, 2024) **Board of Directors**

Committed to ongoing Board refreshment and diversity of background, gender, skills, and experience:

**Director Diversity** 

**3** Female

**1** Veteran Status

89% Board Independence

**Overall Board** 

Diversity

**1** African American

Our mission is to drive sustainability with our partners by incorporating environmental and sustainability principles into all our commercial relationships

### **Diversity, Equity, & Inclusion (DEI)**

Pledge to support a more inclusive culture to impact our employees, our communities, and society.

> We have embedded DEI into our business units, our Belief Statement, and Mission-**Focused Behaviors**

### **Employee Recruitment, Engagement, & Retention**

Leverage employee capabilities and expertise to provide a culture that drives performance and ultimately attracts, energizes, and retains critical talent.

Amicus is Certified as a Great Place to Work in the U.S., U.K., Italy, Germany, Spain, France, and Japan

### **Career Development**

90%

Employees say Amicus is a great place to work compared to 57% of employees at a typical U.S.-based company



### **Pledge for a Cure**

Designate a portion of product revenue back into R&D for that specific disease until there is a cure.

### **Pricing PROMISE**

Committed to never raising the annual price of our products more than consumer inflation.

### **Charitable Giving**

(as of December 31, 2023) **Contributions allocated:** \$1,980,516 U.S. \$706,417 Intl.

**Expanded Access through Feb 2024:** 32 patients / 24 countries

Amicus-supported Volunteer hours (U.S.): community programs: 511 37

## **FX Sensitivity and Galafold Distribution of Quarterly Sales**

### **Impact from Foreign Currency Q1 2024:**

Currency Variances: USD/	Q1 2023	Q1 2024	YoY Variance
EUR	1.073	1.086	1.2%
GBP	1.215	1.268	4.4%
JPY	0.008	0.007	(10.8%)

### Distribution of Galafold Revenue by Quarter over Past 5 Years:

	Q1	Q2	Q3	Q4
5 Year Avg.	22%	24%	26%	28%

### Full-year 2024 Revenue Sensitivity

Given the high proportion of Amicus revenue Ex-US (>60%), a change in exchange rates of +/- 5% compared to year-end 2023 rates could lead to a ~\$15M move in global reported revenues in 2024.



# Streamlined Rare Disease Pipeline with Focus on Fabry Disease and Pompe Disease Franchises

ΙΝ ΟΙ C Α ΤΙΟ Ν	D I S C O V E R Y	P R E C L I N I C A L	PHASE 1/2	PHASE 3	REGULATORY	COMMERCIAL
FABRY FRANCHISE						
Galafold <sup>®</sup> (migalastat)						
Fabry Genetic Medicines						
Next-Generation Chaperone						
POMPE FRANCHISE						
<b>Pombiliti<sup>®</sup></b> (cipaglucosidase alfa-atga) + <b>Opfolda<sup>®</sup></b> (miglustat)						
Pompe Genetic Medicines						
OTHER						
Discovery Programs						

